RESUMO
Tandem mass spectrometry is a powerful approach for the analysis of peptides and proteins due to the primary structural information inherent in the observed products. The fragmentation of peptides and proteins depends heavily on the sequence and ion type of the species of interest. In this perspective special feature article, Scott McLuckey and co-authors show that peptides and proteins containing dehydroalanine, a nonproteinogenic amino acid with an unsaturated side-chain, undergo enhanced cleavage of the N-Cα bond of the dehydroalanine residue to generate c- and z-ions. Since these fragment ion types are not commonly observed upon activation of positively charged even-electron species, they can be used to identify dehydroalanine residues and localize them within the peptide or protein chain. Scott McLuckey is Professor of Chemistry at Purdue University (West Lafayette, IN). His research interests are centered on gas-phase ion chemistry and instrumentation for organic and biological mass spectrometry.
Assuntos
Bacillus cereus/genética , Bacillus cereus/patogenicidade , Bacillus/genética , Toxinas Bacterianas/genética , Queijo/microbiologia , Animais , Bacillus/isolamento & purificação , Bacillus cereus/isolamento & purificação , Bacillus thuringiensis/genética , Bacillus thuringiensis/isolamento & purificação , Proteínas de Bactérias/genética , Toxinas Bacterianas/isolamento & purificação , Indústria de Laticínios , Proteínas Hemolisinas/genética , Leite/microbiologia , Ovinos , Especificidade da EspécieRESUMO
The cardiovascular system is an important target for thyroid hormones. The present study evaluates the changes affecting thyroid hormone metabolism during and 6 days after coronary artery bypass and their relationship with the post-operative outcome of the patients. Thirty-three patients were enrolled in the study; their thyroid hormone profiles were determined at 13 sampling points during surgery and for 6 days afterwards. Serum total tri-iodothyronine (T3) and free T3 (FT3) concentrations decreased significantly after surgery (P<0.001) and they remained significantly low until the end of the study. Free thyroxine (FT4) and T4 declined significantly immediately after surgery (P<0.05 for FT4, P<0.001 for T4) but they returned to baseline values (24 h and 96 h post-surgery respectively). Serum reverse T3 increased remarkably 36 h after surgery (P<0.001) and remained significantly higher than the baseline value throughout the study. A relevant finding was that the days of post-operative hospitalization (10+/-3 days, means+/-S.D.) was inversely correlated with the slope of the recovery of T3 concentration (P<0.001) or with the area under the plasma curves of T3 (P=0.024, time range 72-144 h) and the FT3/FT4 ratio (P=0.037, time range 72-144 h) during the post-operative period. Our data suggest a prolonged reduction of T4 to T3 conversion in patients undergoing cardiac surgery and indicate that the recovery period is the most critical in the evaluation of a possibly successful approach for T3 substitutive therapy.
Assuntos
Ponte de Artéria Coronária , Doença das Coronárias/sangue , Doença das Coronárias/cirurgia , Tri-Iodotironina/sangue , Idoso , Análise de Variância , Área Sob a Curva , Proteínas Sanguíneas/análise , Humanos , Pessoa de Meia-Idade , Período Pós-Operatório , Tireotropina/sangue , Tiroxina/sangue , Resultado do Tratamento , Tri-Iodotironina Reversa/sangueRESUMO
A high incidence of autoimmune Type 1 diabetes mellitus (DM) has been clearly established in Sardinia. Although systematic epidemiological studies are still not available, an increased prevalence of thyroid autoantibodies (ATA) has been documented in the Sardinian adult population as compared to other Italian regions, suggesting that thyroid autoimmune disease may also have increased. We carried out a preliminary study with the aim of determining the prevalence of serological markers of thyroid (anti-thyroperoxydase antibodies, TPOAb) and islet cell (ICA) autoimmunity in a large number (no.=2249) of sera obtained from cord-blood of Sardinian pregnant women at delivery. The prevalence of TPOAb was 11.9%, while ICA were detected in 59 cases (2.6%). A higher prevalence of TPOAb (6/17=35.3%) was found in sera with high ICA titers (> or = 20 JDF-U), as compared to sera with low ICA titers (5-19 JDF-U) and to ICA-negative sera (3/42=7,1%; chi2=5.4, p=0.02 and 258/2190=11,8%; chi2=6.8, p=0.009 respectively). Fourteen women (all ICA-negative) were diabetic: 4 had Type 1 and 10 had gestational DM; due to the low number, no correlation could be established between DM type and TPOAb prevalence and/or titer. These preliminary data indicate that ATA are frequently observed in the general population of Sardinian pregnant women at term. As a consequence, even the frequency of postpartum thyroiditis is expected to be high. Although ATA were not increased in women with clinical overt diabetes, a higher prevalence of ATA was found in women with high titers of circulating ICA. Our results also confirm that Sardinia represents, perhaps for its peculiar genetic characteristics, an ideal place to study organ-specific autoimmunity.
Assuntos
Autoanticorpos/análise , Parto Obstétrico , Iodeto Peroxidase/imunologia , Ilhotas Pancreáticas/imunologia , Gravidez/imunologia , Adolescente , Adulto , Estudos Transversais , Diabetes Gestacional/imunologia , Feminino , Humanos , Itália , Gravidez em Diabéticas/imunologiaRESUMO
Cardiac natriuretic peptide hormones (ANP and BNP) are synthesized and secreted by the heart, producing several biological effects, such as natriuresis, vasorelaxation, hypotension, and neuromodulation. Extensive studies conducted in both animals and humans have documented that cardiac natriuretic peptides (CNPs) are secreted into the circulatory system via the coronary sinus into the right atrium, and then rapidly degraded and removed from the blood by plasma proteases and specific clearance receptors. Usually, studies of CNPs kinetics have been carried out following an experimental protocol in which labeled or unlabeled hormone is administered (by constant infusion or bolus injection) and the corresponding concentration of the hormone is measured in peripheral venous blood. However, when a uniform intravascular concentration throughout artero-venous vessels is lacking due to the very rapid clearance of the substance being studied (such as CNPs), the classical compartmental or none compartmental approach may not be suitable for interpreting the experimental data. In this case, a more physiological circulatory model, which does not assume a uniform intravascular distribution of the hormone and comprises several anatomo-functional blocks arranged in a series and supplied by the same flow (cardiac output) should be adopted. Different experimental designs (infusion or bolus injection) as well as multiple sampling sites (aorta and pulmonary artery, inferior vena cava, femoral vein) were used in ANP kinetic studies. Using a circulatory approach, ANP has been demonstrated to be rapidly distributed and degraded; in healthy subjects about 50% of ANP secreted into the right atrium is extracted by the peripheral tissues during the first pass throughout the body. Since CNPs have important fluid-volume regulatory features, it has been postulated that they also play a key role in volume homeostasis in several pathophysiological states, such as congestive heart failure. Indeed, a markedly altered degradation and distribution of ANP in patients with cardiac failure who show a resistance to its natriuretic effects, even in those on the early stage of clinical disease, whose CNPs plasma levels are in the normal range, have been demonstrated. Recent studies indicate that some drugs, by inhibiting the degradation of CNPs by plasma proteases and can thus affect CNP kinetics, may be useful in the treatment of arterial hypertension and cardiac failure.
Assuntos
Fator Natriurético Atrial/metabolismo , Coração/fisiologia , Miocárdio/metabolismo , Peptídeo Natriurético Encefálico/metabolismo , Animais , Coração/fisiopatologia , Cardiopatias/fisiopatologia , HumanosRESUMO
In an attempt to identify and quantify the sites of atrial natriuretic peptide (ANP) degradation, particularly the lungs, a new tracer method to study ANP metabolism in vivo in humans was developed and applied to patients with left ventricular dysfunction. Thirteen male, normotensive, cardiac patients with different degrees of left ventricular myocardial involvement were enrolled in the study. The study protocol required constant infusion (3 patients) or bolus injection (10 patients) of 125I-labeled ANP just upstream of the right atrium and blood sampling from different sites (pulmonary artery, aorta, inferior vena cava, and femoral vein) during the hemodynamic study. Data analysis was based on a kinetic model consisting of three blocks in series (right heart, lungs and left heart, and periphery) supplied by the same plasma flow (plasma cardiac output). Plasma levels of native ANP were measured with a sensitive and specific immunoradiometric assay method. ANP values measured in the aorta (163.9 +/- 144.8 pg/mL, n = 80) were superimposable on those measured in the pulmonary artery (161.8 +/- 136.5 pg/mL, n = 80). Negligible extraction of 125I-labeled ANP was found in the lungs and left heart block (on average 0.08 +/- 3.92%), whereas the peripheral block extraction (46.2 +/- 7.8%) accounted for almost total hormone removal from the blood (whole body extraction was 46.4 +/- 6.6%). ANP metabolic clearance rate (3.11 +/- 1.48, range 1.4-6.8 L/min) declined with the progression of left ventricular dysfunction (plasma cardiac output 3.46 +/- 1.08, range 1.2-5.7 L/min), and a close correlation between metabolic clearance rate and cardiac output was evident. Our data suggest that lungs do not extract, or extract only very small amounts, of labeled ANP administered iv to patients with different degrees of left ventricular myocardial involvement, and whole body extraction of labeled ANP remains relatively stable with the progression of disease, and the large reductions in clearance values observed in our patients can be ascribed mainly to the reductions in cardiac output.
Assuntos
Fator Natriurético Atrial/metabolismo , Pulmão/metabolismo , Disfunção Ventricular Esquerda/metabolismo , Adulto , Aorta , Fator Natriurético Atrial/sangue , Débito Cardíaco , Veia Femoral , Hemodinâmica , Humanos , Radioisótopos do Iodo , Cinética , Masculino , Pessoa de Meia-Idade , Artéria Pulmonar , Veia Cava Inferior , Disfunção Ventricular Esquerda/fisiopatologiaRESUMO
In an attempt to identify and quantify the sites of atrial natriuretic peptide (ANP) degradation, a new tracer experiment has been developed. 125I-ANP was injected as a bolus just upstream from the right atrium, and blood was sampled from two different sites (pulmonary artery and aorta) in eight cardiac patients. Data were analyzed using a physiologically based circulatory model consisting of three blocks in series (right heart, lungs and left heart, and periphery) supplied by the same flow (cardiac output, measured by thermodilution); the extraction coefficients of the three blocks and of the whole body could be determined from the areas under tracer concentration curves in plasma (AUCs). The values for AUCs (means +/- SD) were 64.8 +/- 9.4 and 65.5 +/- 10.7% dose.l-1.min-1 for pulmonary artery and aorta curves, respectively; the area under the pulmonary artery curve could be subdivided into the area under the first-pass curve (30.6 +/- 4.7% dose. l-1.min-1) and the area under the recirculating curve (34.0 +/- 7.7% dose.l-1.min-1). The metabolic clearance rate of 125I-ANP, computed as dose divided by the area under the recirculating curve, was 3.1 +/- 0.7 l/min, and the whole body extraction was 47.6 +/- 6.6%. In our patients with myocardial dysfunction, neither right heart block nor lungs and left heart block significantly extracted ANP, and periphery block accounted for almost all removal of the hormone from the blood.
Assuntos
Fator Natriurético Atrial/sangue , Modelos Cardiovasculares , Adulto , Feminino , Cardiopatias/metabolismo , Humanos , Radioisótopos do Iodo , Cinética , Masculino , Pessoa de Meia-Idade , Traçadores RadioativosRESUMO
The applicability of circulatory model approach for determining the kinetic parameters of endogenously produced substances has been demonstrated based on the assumption that the behaviour of newly produced molecules of a compound inside its production spaces is the same as that of the molecules returned due to recirculation of blood. While extraction and transmission parameters can be estimated by using tracer data, total mass cannot be determined without additional information. This information could be obtained from data of some suitable metabolite by using double tracer method. Circulatory model is especially suitable for studies of substances with a fast kinetics and renewal if blood (plasma) flow is measured independently.
Assuntos
Circulação Sanguínea , Modelos Cardiovasculares , Farmacocinética , RadioisótoposRESUMO
Atrial natiurectic peptide (ANP) is a cardiac hormone with a very short plasma half-life, which plays an important role in a variety of clinical conditions associated with an increase in pressure and/or volume overload on the heart. The MCR of the hormone is considered to represent a stable parameter, reflecting the uptake and degradation rate of ANP by the periphery, only scarcely affected by rapid oscillations of circulating levels. To evaluate the extent to which MCR is affected by rapid and large variations of circulating levels of the hormone, we measured MCR in five patients with different degrees of myocardial function (from normal to severely impaired), in whom changes in ANP levels were induced by atrial and/or ventricular pacing. Cardiac output was simultaneously measured by thermodilution to calculate whole body extraction of ANP. During constant i.v. infusion of [125I]ANP, the hormone MCR was determined both under basal conditions (at tracer equilibration, 20-30 min after the start of infusion) and during atrial and ventricular pacing. Pacing maneuvers, begun 50 min after the start of infusion, induced a marked and rapid increase in endogenous plasma ANP values in all patients (on the average, 3,7-fold compared to basal values; range, 1.8-5.68), whereas corresponding values of [125I]ANP only minimally changed. The MCR of ANP (3.62 +/- 1.06 L/min, mean +/- SD) slightly decreased (by repeated measures ANOVA, P = 0.0458) during atrial and ventricular pacing procedures (3.35 +/- 1.03 and 3.15 +/- 0.74 L/min, respectively), reaching a mean value of 88.7 +/- 9.0% compared to basal. The small decrease in MCR could be almost completely ascribed to hemodynamic factors; indeed, basal cardiac output (5.76 +/- 1.70 L/min) was found, on the average, to be slightly decreased during atrial and ventricular pacing (5.28 +/- 1.46 and 5.16 +/- 1.33 L/min, respectively), and so whole body extraction of the hormone, measured before pacing (50.0 +/- 12%), remains stable throughout the study period (50.4 +/- 10.6% and 49.6 +/- 10% during atrial and ventricular pacing, respectively). Our findings demonstrate that degradative mechanisms involved in ANP clearance are not saturable at least for acute elevations of ANP plasma levels up to 3-5 times the basal level.
Assuntos
Fator Natriurético Atrial/metabolismo , Estimulação Cardíaca Artificial , Adulto , Idoso , Função Atrial , Fator Natriurético Atrial/sangue , Débito Cardíaco , Feminino , Humanos , Masculino , Taxa de Depuração Metabólica , Pessoa de Meia-Idade , Função VentricularAssuntos
Antígeno Prostático Específico/sangue , Coleta de Dados , Humanos , Imunoensaio , MasculinoRESUMO
Beginning in 1987, an external quality assessment (EQA) scheme for cyclosporine (CsA) assay was organized by our Institute and supported by National Research Council (CNR); in 1991, the CNR EQA joined the French CsA interlaboratory program organized by Service de Radiopharmacie et Radioanalyse, University of Lyon. During the last 2 years (1993 and 1994 cycles), > 170 laboratories (from seven European countries) participated in this survey, assaying 44 control samples prepared from pooled blood of heart- and renal-transplant patients; normal pools added with known amounts of CsA were also distributed. During the whole EQA period, a trend toward the use of specific and nonisotopic techniques has been observed. In 1994, 91% of the collected results have been produced by specific methods [high-pressure liquid chromatography (HPLC) or specific immunoassays developed to assay the native molecule of CsA without its metabolites];in the same cycle, the fully automated techniques [TDx, fluorescence polarization immunoassay (FPIA), and enzyme-multiplied immunoassay (EMIT)] accounted for 73% of total results. CsA concentration measured by monoclonal specific immunoassays [(TDx FPIA, radioimmunoassay (RIA) Cyclo-Trac, and EMIT] was well correlated with those from HPLC (r = 0.99-1.00); results from EMIT were very close to those from HPLC, whereas results from RIA Cyclo-Trac and TDx were slightly overestimated (10-20%). Nonspecific methods (TDx polyclonal and nonspecific RIA Cyclo-Trac) measured CsA concentrations 3-4 times higher than those found by HPLC. The cross-reactivity of CsA metabolites in specific immunoassays was estimated from data of patients' samples and spiked samples; an interference of 6% in RIA Cyclo-Trac, 7% in EMIT, and 26% in TDx FPIA was found. The precision coefficient of variation (CV% between laboratory and between assay) of the methods observed in the 1994 EQA cycle was 9.5 for TDx polyclonal FPIA, 10.4 for TDx monoclonal FPIA, 10.5 for EMIT, 10.6 for RIA specific Cyclo-Trac, 14.2 for RIA nonspecific Cyclo-Trac, and 15.2 for HPLC.
Assuntos
Ciclosporina/sangue , Imunossupressores/sangue , Anticorpos Monoclonais , Especificidade de Anticorpos , Cromatografia Líquida de Alta Pressão , Técnica de Imunoensaio Enzimático de Multiplicação , Estudos de Avaliação como Assunto , Imunoensaio de Fluorescência por Polarização , Humanos , Controle de Qualidade , Radioimunoensaio , Análise de RegressãoRESUMO
Amiodarone, an antiarrhythmic agent, is also known to have important effects on the peripheral metabolism of thyroid hormones; the relationship between these two effects of the drug, however, is not well established. We tested the hypothesis that the antiarrhythmic effect of amiodarone might be mediated by its effect on the metabolism of thyroid hormones. Peripheral thyroid hormone metabolism was investigated using a double-tracer ([125I]-T4 and [131I]-T3) procedure in 10 normal volunteers and 10 euthyroid patients with complex ventricular arrhythmias before and during 6 months' amiodarone treatment. The underlying cardiac disease was coronary artery disease in four cases, dilated cardiomyopathy in three and idiopathic arrhythmias in three. In all but one patient with complex ventricular arrhythmias amiodarone treatment resulted in a reduction of > or = 80% of premature ventricular contractions and complete suppression of episodes of ventricular pairs or ventricular tachycardia. In all cases successful treatment with amiodarone was accompanied by normalization of all kinetic parameters: T4 to T3 conversion ratio and T3/T4 molar ratio of production decreased to mean values of 24.7 +/- 17.5% and 0.35 +/- 0.22% respectively, whereas T4 production rate increased (mean value 75.9 +/- 30.0 nmol day-1 m-2). Our kinetic data indicate that long-term therapy with amiodarone, when effective in suppressing cardiac arrhythmias, also reduces peripheral T4 to T3 conversion, hence restoring the normal peripheral thyroid hormone metabolic pattern. In conclusion, our study confirms that the antiarrhythmic action of amiodarone may be (at least partially) mediated by its action on thyroid hormone metabolism, and may justify the hypothesis that an altered peripheral metabolism of thyroid hormones may play a role in the pathogenesis of complex ventricular arrhythmias.
Assuntos
Amiodarona/uso terapêutico , Antiarrítmicos/uso terapêutico , Taquicardia Ventricular/tratamento farmacológico , Tiroxina/metabolismo , Tri-Iodotironina/metabolismo , Idoso , Idoso de 80 Anos ou mais/fisiologia , Análise de Variância , Complexos Cardíacos Prematuros/tratamento farmacológico , Feminino , Humanos , Cinética , Masculino , Pessoa de Meia-Idade , Tiroxina/sangue , Tri-Iodotironina/sangueRESUMO
Data collected in the 1993 and 1994 cycles of an international External Quality Assessment (EQA) programme were cumulatively analysed to evaluate the analytical performance of the methods currently in use for routine assay of mucinous tumour markers CA 19-9, CA 15-3 and CA 125. On average the between-laboratory variability was 14.7 and 15.8 CV% for CA 15-3 and CA 125 respectively. For CA 19-9, a markedly worse between-laboratory variability (on average 27.2 CV%) was found; the agreement of CA 19-9 results worsened in the last few years when new isotopic techniques became available. The variability component attributable to systematic differences between methods/kits was relatively small for CA 15-3 and CA 125 (17% and 21% of the total variability), while it was markedly larger for CA 19-9 (45% of the total variability). The precision of the methods/kits most often used in the survey ranged from 9.6 to 13.9 CV% for CA 125 and from 10.8 to 14.1 CV% for CA 15-3. For these two tumour markers the precision of the traditional IRMAs does not appear to be different from that of the new fully automated non-isotopic techniques. The precision of CA 19-9 methods was on average worse from (11.9 to 19.2 CV%), even though the precision of the two automated systems was better than that of IRMAs. In conclusion, the results of this study indicate that the between-laboratory agreement for CA 15-3 and CA 125 assays appears satisfactory while the CA 19-9 assay shows larger differences between methods and is affected by poorer precision of kits.
Assuntos
Antígenos Glicosídicos Associados a Tumores/sangue , Biomarcadores Tumorais/sangue , Imunoensaio/normas , Kit de Reagentes para Diagnóstico/normas , Antígeno Ca-125/sangue , Antígeno CA-19-9/sangue , Estudos de Avaliação como Assunto , Humanos , Cooperação Internacional , Mucina-1/sangue , Controle de QualidadeRESUMO
BACKGROUND: Atrial natriuretic peptide (ANP) has been suggested to play an important role in heart failure, preserving cardiorenal homeostasis through maintenance of the sodium balance and inhibition of the detrimental effects of the neurohormonal vasoconstrictor system. The current study was designed to investigate whether there is a disturbed renewal and distribution of ANP in patients with idiopathic dilated cardiomyopathy (IDC) with differing clinical severity of disease. METHODS AND RESULTS: We used a tracer method to perform a cross-sectional study of 15 IDC patients with differing clinical severity (New York Heart Association functional class I to III), prospectively divided into two groups according to their functional class (group 1, classes I and II; group 2, classes II-III and III). Eleven normotensive, nonobese male volunteers also were studied as a control group. Main ANP kinetic parameters were derived from the disappearance curve of the labeled hormone after the bolus injection of [125I]-labeled ANP. A high-performance liquid chromatography technique was used to separate the radiolabeled hormone in each plasma sample. Patients in group 1 showed higher ANP metabolic clearance rate (MCR) (2731.9 +/- 726.2 mL.min-1.m-2) than patients of group 2 (1718.4 +/- 621.2 mL.min-1.m-2) and control subjects (1873.1 +/- 551.2 mL.min-1.m-2). ANP disposal (MCR) positively correlated with biological hormonal effect (urinary sodium excretion) both in control subjects and in patients. In IDC patients of both groups, however, MCR values were always higher (approximately doubled) than the values found in control subjects at the corresponding sodium excretion. This finding indicates that a reduced ANP biological activity is associated with hormone degradation in patients. Moreover, patients of group 2 showed significantly higher ANP production rates (395.6 +/- 183.8 ng.min-1.m-2) than group 1 (166.0 +/- 139.0 ng.min-1.m-2) and control subjects (130.7 +/- 105.4 ng.min-1.m-2) despite a marked reduction in sodium excretion. Patients with IDC showed a progressive reduction in the total distribution volume (group 1, 19.8 +/- 5.8 L/m2; group 2, 12.7 +/- 6.9 L/m2; control subjects, 27.0 +/- 11.6 L/m2) of the hormone; this probably was due to a reduction in exchanges of ANP with peripheral tissues. CONCLUSIONS: Our study demonstrates a markedly altered degradation and distribution of ANP in patients with IDC, even in those at the early stage of clinical disease (classes I and II, group 1) who have ANP plasma levels in the normal range.
Assuntos
Fator Natriurético Atrial/metabolismo , Cardiomiopatia Dilatada/metabolismo , Sódio/urina , Adulto , Aldosterona/sangue , Fator Natriurético Atrial/sangue , Fator Natriurético Atrial/farmacocinética , Cardiomiopatia Dilatada/diagnóstico , Cromatografia Líquida de Alta Pressão , Estudos Transversais , Humanos , Radioisótopos do Iodo , Masculino , Taxa de Depuração Metabólica , Pessoa de Meia-Idade , Estudos Prospectivos , Radioimunoensaio , Renina/sangue , Sistema Renina-Angiotensina/fisiologia , Índice de Gravidade de Doença , Fatores de Tempo , Distribuição TecidualRESUMO
Using a tracer method, we evaluated, in vivo, the main turnover parameters and the main metabolic pathways of ANP in 10 normal subjects. HPLC was used to purify the labeled hormone and the principal labeled metabolites present in venous plasma samples collected at determined times after tracer injection. The main ANP kinetic parameters were derived from the disappearance curves of [125I] ANP, which were satisfactorily fitted by a biexponential function in all subjects. Newly produced ANP initially distributes in a large, plasma equivalent space (10.9 +/- 3.6 l/m2 body surface); the hormone rapidly leaves this space due to both degradation and to distribution in peripheral spaces. The mean residence time in the body (19.4 +/- 19.8 min) and the plasma equivalent total distribution volume (28.2 +/- 11.5 l/m2) indicate that ANP is also widely distributed outside the initial space in humans (circulating ANP is no more than 1/15 of the body pool). Metabolic clearance rate values were distributed across a wide range (from 740 ml/min/m2 to 2581 ml/min/m2, mean 1849 ml/min/m2), and were shown to strongly correlate (R = 0.962) with the daily urinary excretion of sodium. A complete separation of labeled ANP from its labeled metabolites was achieved by the HPLC technique; at least 3 different peaks due to labeled metabolites in vivo produced from the injected [125I]ANP1-28 were found. The first chromatographic peak eluted showed an identical elution time to monoiodotyrosine. At least two other peaks due to in vivo generated labeled metabolites were well identified in the chromatograms: one peak (coeluting with labeled COOH-terminal tripeptide, H-Phe-Arg-Tyr-OH) was eluted ahead and one (coeluting with labeled peptide fragments ANP7-28, ANP13-28, and ANP18-28) behind the elution peak of the labeled ANP. The peak of labeled tyrosine appearing in the plasma ranged between 3 and 5 min after tracer injection; the other two peaks of radioiodinated metabolites showed their highest activity in the first sample (1.5 min), suggesting an earlier occurrence of their peaks. These labeled metabolites seem to be intermediate peptides, between the intact circulating form of the hormone and the final labeled metabolite (tyrosine), which is the last amino acid of the peptide hormone, produced in vivo after injection of the tracer.(ABSTRACT TRUNCATED AT 400 WORDS)
Assuntos
Fator Natriurético Atrial/sangue , Adulto , Sequência de Aminoácidos , Humanos , Radioisótopos do Iodo , Cinética , Masculino , Pessoa de Meia-Idade , Dados de Sequência Molecular , Fragmentos de Peptídeos/sangue , Tirosina/sangueRESUMO
Data collected in the 1993 and 1994 cycles of an international external quality assessment (EQA) program and in a national multicenter collaborative study were cumulatively analyzed to evaluate the standardization of the methods currently in use for the assay of mucinous tumor markers CA 19-9, CA 15-3 and CA 125. On average the between-laboratory variability was 15.2 and 16.0 CV% for CA 15-3 and CA 125 respectively; the between-laboratory variability found for CA 19-9 was markedly worse (mean 28.3 CV%). The variability component attributable to systematic differences between different methods/kits was relatively small for CA 15-3 and CA 125 (18% and 24% of the total variability) but markedly larger for CA 19-9 (48% of the total variability). The agreement of CA 19-9 results worsened in the last few years when new nonisotopic techniques became available. The precision of the methods/kits most used in the survey ranged from 9.9 to 13.3 CV% for CA 125 and from 11.6 to 13.9 CV% for CA 15-3. For these two tumor markers the precision of the traditional IRMAs does not appear different from that of the new fully automated nonisotopic techniques. The precision of CA 19-9 methods was on average worse (from 11.7 to 19.6 CV%) although two automated systems exhibited a precision better than that of IRMAs. In conclusion, the results of this study indicate that CA 15-3 and CA 125 are satisfactorily assayed whereas CA 19-9 assay appears affected by larger differences between methods and by poorer precision of laboratories and kits.
Assuntos
Antígenos Glicosídicos Associados a Tumores/sangue , Imunoensaio , Qualidade da Assistência à Saúde , Antígeno Ca-125/sangue , Antígeno CA-19-9/sangue , Antígeno Carcinoembrionário/sangue , Humanos , Imunoensaio/métodos , Imunoensaio/normas , Ensaio Imunorradiométrico , Cooperação Internacional , Itália , Mucina-1/sangue , Antígeno Prostático Específico/sangue , Análise de Regressão , alfa-Fetoproteínas/metabolismoRESUMO
OBJECTIVE: To evaluate microvascular permeability by the transcapillary escape rate of albumin (TERalb) in type II diabetic patients with normo- and microalbuminuria. RESEARCH DESIGN AND METHODS: The TERalb has been measured following intravenous injection of 125I-labeled human serum albumin in 32 normotensive type II diabetic patients and 9 healthy control subjects matched for sex and age. Type II diabetic subjects were grouped in normoalbuminuric, albumin excretion rate (AER) < 20 micrograms/min (n = 18), and microalbuminuric, AER 20-200 micrograms/min (n = 14) categories. RESULTS: In type II diabetic patients, no differences were noted between normo- and microalbuminuric groups for known diabetes duration (8.3 +/- 5.9 vs. 11.7 +/- 8.0 years), blood pressure (BP) (129/76 +/- 16/8 vs. 131/76 +/- 14/5 mmHg), current metabolic control (HbA1c: 8.0 +/- 1.4 vs. 8.5 +/- 1.6%), and serum lipids. However, previous 2-year mean HbA1c levels were significantly higher in microalbuminuric patients (8.7 +/- 1.45 vs. 7.6 +/- 1.29%; P < 0.05). The TERalb was similar in control subjects and normoalbuminuric patients (5.16 +/- 1.09 vs. 5.71 +/- 1.66 %/h) and significantly higher in the microalbuminuric group (8.98 +/- 1.35 %/h; P < 0.0001). The increased leak of albumin was not explained by differences in diabetes duration, BP, or metabolic control at the time of investigation and was independently related to the presence of microalbuminuria (r = 0.63, percent explained variance approximately 40) and mean "historical" HbA1c (multiple r = 0.705; total explained variance approximately 50%). CONCLUSIONS: Type II diabetic patients with microalbuminuria show an increased TERalb, i.e., a widespread microvascular damage that may be important in the pathogenesis of long-term complications. Our findings may contribute to the explanation of why albuminuria seems to be an independent cardiovascular risk factor in type II diabetes.
Assuntos
Albuminúria/metabolismo , Permeabilidade Capilar/fisiologia , Diabetes Mellitus Tipo 2/metabolismo , Albumina Sérica/metabolismo , Albuminúria/etiologia , Análise de Variância , Cromatografia Líquida de Alta Pressão , Diabetes Mellitus Tipo 2/complicações , Feminino , Humanos , Radioisótopos do Iodo , Masculino , Pessoa de Meia-Idade , Inquéritos e QuestionáriosRESUMO
Atrial natriuretic peptide (ANP) kinetics was studied in 12 patients with idiopathic dilated cardiomyopathy at different sodium excretion (30-175 mmol/day) and variable degrees of hemodynamic dysfunction [New York Heart Association (NYHA) class range I-III] to investigate whether differences in renewal and distribution of this hormone (as compared with those of a control group) play a role in pathogenesis and evolution of heart failure. [125I]Labeled ANP was injected as a bolus, and a high-performance liquid chromatography (HPLC) procedure was used to purify the labeled hormone in venous plasma samples collected for < or = 50 min after injection; the main ANP kinetic parameters were then derived from the disappearance curve of the labeled hormone. As in controls, a positive linear regression between ANP metabolic clearance rate (MCR, ml/min/m2) values and daily urinary excretion of sodium (NaUE, mmol/day) was noted in patients. The different linear regression coefficients between normal subjects (MCR = 365 +/- 8.08 NaUE, r = 0.986, p < 0.0001) and patients (MCR = 497 + 18.5 NaUE, r = 0.867, p = 0.001) indicate that in patients a higher peptide clearance rate is needed to obtain the same biologic effect (sodium excretion) and suggest that resistance to biologic effects of the hormone exists in patients at an early stage of disease (NYHA class I). When the efficiency of the ANP system in excreting sodium was expressed as the ratio of NaUE to ANP production rate (PR = MCR x ANP plasma concentration, microgram/day/m2) patients showed significantly lower values (p = 0.0126) than normal volunteers, thus confirming resistance to the hormone effects. Significantly lower values for ANP total distribution volume (16.5 +/- 8.4 L/m2), mean residence time in the sampling space (4.04 +/- 1.14 min), mean residence time in the body (7.25 +/- 2.13 min), and fewer recycles through the initial (sampling) space (0.27 +/- 0.16) were noted in patients, indicating an altered mechanism regulating distribution of the hormone. The positive correlations between ANP MCR (L/min/m2) values and cardiac index (CI, L/min/m2) (MCR = -1.24 + 1.17 CI, r = 0.689, p = 0.0092) and between initial distribution volume (IDV, L/m2) and CI (IDV = -11.2 + 6.85 CI, r = 0.730, p = 0.0046) in all patients indicate that hemodynamic factors contribute to the progressive reduction in MCR and IDV values throughout the progression of myocardial involvement.(ABSTRACT TRUNCATED AT 400 WORDS)